Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

For tough AML, half respond to selinexor plus chemotherapy

Key clinical point: Patients with relapsed or refractory acute myeloid leukemia may be more likely to respond when selinexor is added to standard chemotherapy.

Major finding: The overall response rate was 50% for patients receiving cytarabine, idarubicin, and selinexor.

Study details: A phase 2 trial involving 44 patients with relapsed or refractory acute myeloid leukemia.

Disclosures: The study was funded by Karyopharm Therapeutics. Dr. Fielder reported financial disclosures related to Amgen, Pfizer, Jazz Pharmaceuticals, and other companies.

Citation:

Fiedler W et al. EHA Congress, Abstract S880.